This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HELE or EL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HELE vs. EL: Which Stock Is the Better Value Option?
Should Value Investors Buy Helen of Troy (HELE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Molson Coors Gains 14.5% in 6 Months: Should You Buy the Stock?
by Zacks Equity Research
TAP makes significant progress on its premiumization strategy. The company has been investing in building the brand's awareness and consumer base.
HELE or LRLCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HELE vs. LRLCY: Which Stock Is the Better Value Option?
Should Value Investors Buy Helen of Troy (HELE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Newell's Q4 Earnings Surpass Estimates, Lower Core Sales Hurt
by Zacks Equity Research
NWL reports a sales decline in fourth-quarter 2024, owing to a core sales drop of 3% year over year.
Helen of Troy (HELE) Down 2.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Helen of Troy (HELE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Philip Morris Q4 Earnings & Sales Beat Estimates, Stock Rallies
by Zacks Equity Research
PM's fourth-quarter 2024 results reflect increased earnings and sales on robust momentum across all regions.
KDP's Brands & Pricing Actions Seem Good: Apt to Hold the Stock?
by Zacks Equity Research
Keurig Dr Pepper gains from innovation and solid performance in its Refreshment Beverages segment.
Mondelez Q4 Earnings Miss Estimates Amid Increased Cocoa Costs
by Zacks Equity Research
MDLZ's fourth-quarter earnings decline year over year amid a challenging operating environment marked by cocoa cost inflation.
Wall Street Analysts See a 28.41% Upside in Helen of Troy (HELE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.4% in Helen of Troy (HELE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Colgate Q4 Earnings Beat, Strong Volume and Pricing Drive Results
by Zacks Equity Research
CL's Q4 results show continued gains from volume and pricing, leading to organic sales growth in five of the six divisions. Improved gross margins aid EPS growth.
MO Q4 Earnings Beat Estimates on Pricing Despite Low Cigarette Volumes
by Zacks Equity Research
Altria's Q4 results reflect increased earnings on higher operating income. Management expects earnings growth in 2025.
HELE vs. EL: Which Stock Is the Better Value Option?
by Zacks Equity Research
HELE vs. EL: Which Stock Is the Better Value Option?
Kimberly-Clark Meets Q4 Earnings Estimates, Announces Dividend Hike
by Zacks Equity Research
KMB's Q4 sales and earnings decline year over year. However, organic sales rise on improved volumes and pricing.
Are Investors Undervaluing Helen of Troy (HELE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Industry Outlook The Estee Lauder, Helen of Troy and European Wax Center
by Zacks Equity Research
The Estee Lauder, Helen of Troy and European Wax Center have been highlighted in this Industry Outlook article.
3 Resilient Cosmetic Stocks to Monitor in a Challenging Market
by Ansuiya Mohta
Despite facing macroeconomic challenges, companies like EL, HELE and EWCZ look well-positioned on digital innovation and strategic initiatives.
Coty Stock Down 42% in a Year: Can the Beauty Giant Recover in 2025?
by Zacks Equity Research
COTY is facing challenges like higher operational costs, weak performance in key international markets and unfavorable currency rates.
Has Freshpet (FRPT) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Here is how Freshpet (FRPT) and Helen of Troy (HELE) have performed compared to their sector so far this year.
NUS Q4 Preliminary Revenues Reach Top End of Outlook, Stock Gains 9.8%
by Zacks Equity Research
Nu Skin's shares rally as the company stated that its preliminary revenues for Q4 came in at the upper end of its projected range.
HELE or EL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HELE vs. EL: Which Stock Is the Better Value Option?
Is Helen of Troy (HELE) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HELE Tops Q3 Earnings Estimates, Narrows Sales & Profit Guidance
by Zacks Equity Research
Helen of Troy's Q3 results reflect a tough consumer spending landscape. While Home & Outdoor unit sales increase, Beauty & Wellness sales decline.
Compared to Estimates, Helen of Troy (HELE) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Helen of Troy (HELE) give a sense of how the business performed in the quarter ended November 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.